PHIO - Phio Pharma's PH-762 shows antitumor activity in HER2-targeted CAR-T cells in solid tumors in mice

Phio Pharmaceuticals (PHIO) announces positive new in vivo data showing that PH-762 significantly enhanced the antitumor efficacy of HER2-targeted CAR-T cells (HER2CART) in solid tumors.A statistically significant and durable inhibition of tumor growth was seen in PH-762-treated HER2CART cells compared to untreated ones in HER2-expressing SKOV3 model of human ovarian cancer in mice.Analyses of PH-762-treated HER2CART cells isolated from tumors suggest that PH-762 enhances CAR-T function through multiple mechanisms including enhanced efficiency, degranulation, decreased suppressive potential, and promotion of memory/stem populations.On-target silencing of PD-1 in vitro was demonstrated in a dose associated manner in activated HER2CART cells, without significant impact on viability, and resulted in an enrichment of CD8+ and CD25+ cells.These data were presented at the 24th Annual Meeting of the ASGCT.PHIO shares down 8% premarket trading at $2.35.

For further details see:

Phio Pharma's PH-762 shows antitumor activity in HER2-targeted CAR-T cells in solid tumors in mice